Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Acalabrutinib

FDA-approved product (capsule, oral), marketed as Calquence.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Acalabrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Mantle cell lymphoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Acalabrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Acalabrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

    NCT04116437 · start 2019-10-15

    Registered record
    Registry ID
    NCT04116437
    Conditions
    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
    Interventions
    Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-10-15
    Completion
    2026-01-09
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
    InterventionZanubrutinib
    PhasePhase 2
    Registry statusCompleted

  • Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

    NCT03868722 · start 2019-10-11

    Registered record
    Registry ID
    NCT03868722
    Conditions
    CLL
    Interventions
    Acalabrutinib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2019-10-11
    Completion
    2030-07-31
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCLL
    InterventionAcalabrutinib; Venetoclax
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

    NCT04016805 · start 2019-08-05

    Registered record
    Registry ID
    NCT04016805
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Ublituximab; Umbralisib; Ibrutinib; Venetoclax; Acalabrutinib Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-08-05
    Completion
    2022-05-22
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionUblituximab; Umbralisib; Ibrutinib; Venetoclax +1 more
    PhasePhase 2
    Registry statusTerminated

  • Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    NCT04094142 · start 2019-07-09

    Registered record
    Registry ID
    NCT04094142
    Conditions
    Non-hodgkin Lymphoma,B Cell
    Interventions
    Acalabrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-07-09
    Completion
    2022-05-15
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-hodgkin Lymphoma,B Cell
    InterventionAcalabrutinib
    PhasePhase 2
    Registry statusCompleted

  • Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

    NCT03787264 · start 2019-01-14

    Registered record
    Registry ID
    NCT03787264
    Conditions
    Chronic Lymphoid Leukemia
    Interventions
    Bendamustine; Obinutuzumab; Acalabrutinib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-01-14
    Completion
    2023-09-26
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphoid Leukemia
    InterventionBendamustine; Obinutuzumab; Acalabrutinib; Venetoclax
    PhasePhase 2
    Registry statusCompleted

  • HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)

    NCT03685708 · start 2018-12-07

    Registered record
    Registry ID
    NCT03685708
    Conditions
    Hepatitis; Safety and Tolerability
    Interventions
    HEPLISAV-B
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-12-07
    Completion
    2020-12-16
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis; Safety and Tolerability
    InterventionHEPLISAV-B
    PhasePhase 2
    Registry statusCompleted

  • Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    NCT03516617 · start 2018-09-10

    Registered record
    Registry ID
    NCT03516617
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Acalabrutinib; Laboratory Biomarker Analysis; Obinutuzumab; Patient Observation; Quality-of-Life Assessment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2018-09-10
    Completion
    2030-10-16
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionAcalabrutinib; Laboratory Biomarker Analysis; Obinutuzumab; Patient Observation +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

    NCT03527147 · start 2018-06-19

    Registered record
    Registry ID
    NCT03527147
    Conditions
    NHL; DLBCL; Non-hodgkin's Lymphoma; Diffuse Large B Cell Lymphoma
    Interventions
    AZD9150; Acalabrutinib; AZD6738; Hu5F9-G4; Rituximab; AZD5153
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-19
    Completion
    2021-03-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNHL; DLBCL; Non-hodgkin's Lymphoma; Diffuse Large B Cell Lymphoma
    InterventionAZD9150; Acalabrutinib; AZD6738; Hu5F9-G4 +2 more
    PhasePhase 1
    Registry statusCompleted

  • A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

    NCT03328273 · start 2018-01-31

    Registered record
    Registry ID
    NCT03328273
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Ceralasertib; Acalabrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2018-01-31
    Completion
    2026-08-26
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionCeralasertib; Acalabrutinib
    PhasePhase 1
    Registry statusActive not recruiting

  • A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)

    NCT03571308 · start 2017-06-02

    Registered record
    Registry ID
    NCT03571308
    Conditions
    Non Hodgkin Lymphoma
    Interventions
    R-CHOP + acalabrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-06-02
    Completion
    2023-08-31
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Hodgkin Lymphoma
    InterventionR-CHOP + acalabrutinib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

    NCT02972840 · start 2017-04-05

    Registered record
    Registry ID
    NCT02972840
    Conditions
    Lymphoma, Mantle Cell
    Interventions
    Acalabrutinib; Bendamustine; Rituximab; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2017-04-05
    Completion
    2027-02-15
    Enrolment
    635

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, Mantle Cell
    InterventionAcalabrutinib; Bendamustine; Rituximab; Placebo
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole

    NCT04876807 · start 2016-01-28

    Registered record
    Registry ID
    NCT04876807
    Conditions
    Healthy Volunteers
    Interventions
    ACP-196; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-01-28
    Completion
    2016-03-15
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionACP-196; Omeprazole
    PhasePhase 1
    Registry statusCompleted

  • Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

    NCT02570711 · start 2015-10-13

    Registered record
    Registry ID
    NCT02570711
    Conditions
    Metastatic Pancreatic Cancer
    Interventions
    ACP-196; Nab-paclitaxel; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-10-13
    Completion
    2016-04
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Pancreatic Cancer
    InterventionACP-196; Nab-paclitaxel; Gemcitabine
    PhasePhase 2
    Registry statusTerminated

  • Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

    NCT02477696 · start 2015-07-28

    Registered record
    Registry ID
    NCT02477696
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Acalabrutinib; Ibrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2015-07-28
    Completion
    2028-01-03
    Enrolment
    533

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionAcalabrutinib; Ibrutinib
    PhasePhase 3
    Registry statusActive not recruiting

  • ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

    NCT02362048 · start 2015-05

    Registered record
    Registry ID
    NCT02362048
    Conditions
    Metastatic Pancreatic Cancer
    Interventions
    ACP-196; ACP-196 in combination with pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-05
    Completion
    2017-03
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Pancreatic Cancer
    InterventionACP-196; ACP-196 in combination with pembrolizumab
    PhasePhase 2
    Registry statusCompleted